Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.[2][3]
History
Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.[4] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.[5]
In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.[6][7]
See also
External links
References
- Beam Therapeutics Inc. FORM 10-K U.S. Securities and Exchange Commission, retrieved 14 December 2022^
- Why Beam Therapeutics Climbed 64.5% in June NASDAQ^
- John Sterling. Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy GEN - Genetic Engineering and Biotechnology News, 2021-07-15, retrieved 2021-08-07^
- Walter Isaacson. The Code Breaker Simon & Schuster, 2021^
- Andrew Dunn. Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma Business Insider, retrieved 2021-08-07^
- Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases Pfizer^
- Bill Alpert. Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases www.barrons.com, retrieved 2022-02-04^